Is GHRP-2 safe?

Both are synthetic GHRPs that bind the ghrelin receptor to trigger GH release. GHRP-2 (second-generation) produces higher peak GH output and causes less appetite stimulation than GHRP-6 (first-generation). GHRP-6 has deeper research on cardioprotective and gastroprotective properties due to its longer history in the literature. For GH maximization with controlled appetite, GHRP-2 is typically preferred.

Ipamorelin is the most selective GHRP — it stimulates GH release without meaningful increases in cortisol, prolactin, or appetite. GHRP-2 produces stronger GH pulses but raises cortisol and prolactin to a moderate degree. Ipamorelin is considered the "cleaner" choice; GHRP-2 the "more potent" choice. Neither is more evidenced in humans — both lack large clinical trials for body composition outcomes.

Pralmorelin (the clinical name for GHRP-2) is used in some countries, particularly Japan, as a diagnostic test for growth hormone deficiency. A standardized dose is injected and GH is measured at intervals — a blunted GH response suggests GH deficiency. This clinical use provides meaningful human pharmacology data on GHRP-2's GH-stimulating effects, though the diagnostic context differs from performance use.

These operate differently. CJC-1295 is a GHRH analog that extends GH pulse duration; Ipamorelin is a GHRP that triggers GH pulse amplitude. The CJC-1295 + Ipamorelin stack is one of the most widely used GH secretagogue combinations because the two mechanisms are synergistic. GHRP-2 could replace ipamorelin in such a stack for a stronger GH pulse at the cost of more cortisol and prolactin elevation. Most clinicians prefer ipamorelin for its cleaner profile.